Wave Life Sciences (WVE) Liabilities and Shareholders Equity (2014 - 2026)

Wave Life Sciences (WVE) has 13 years of Liabilities and Shareholders Equity data on file, last reported at $558.3 million in Q2 2026.

• Quarterly Liabilities and Shareholders Equity rose 121.24% year-over-year to $558.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $2.0 billion (up 61.56% YoY) and the FY2025 annual result came in at $638.5 million, up 81.29% from the prior year.
• Liabilities and Shareholders Equity eased to $558.3 million in Q2 2026, from $583.5 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $638.5 million in Q4 2025 to a low of $146.4 million in Q4 2022.
• A 5-year average of $299.9 million and a median of $246.9 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2025 — Liabilities and Shareholders Equity plunged 32.67% — and 2026, when it jumped 121.24%.
• Tracing WVE's Liabilities and Shareholders Equity over 5 years: stood at $146.4 million in 2022, then surged by 87.82% to $274.9 million in 2023, then climbed by 28.1% to $352.2 million in 2024, then soared by 81.29% to $638.5 million in 2025, then slipped by 12.56% to $558.3 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $558.3 million (Q2 2026), $583.5 million (Q1 2026), and $638.5 million (Q4 2025), per Business Quant data.